Table V.
Two-way SNP interactions: distribution of combined genotypes in the case (n=106) and control (n=212) populations and associated DTC risk (crude and adjusted ORs).a
| Genotype frequency | DTC risk | ||||||
|---|---|---|---|---|---|---|---|
| Genotype | Controls n (%) | Cases n (%) | P-valueb | OR (95% CI) | P-valueb | Adjusted OR (95% CI)c | P-valueb |
| MSH6 rs1042821-MSH3 | 209 (100) | 105 (100) | 0.167 | ||||
| rs26279 | |||||||
| Gly/Gly-Thr/Thr | 59 (28.2) | 29 (27.6) | 1 (reference)e | 1 (reference)e | |||
| Gly/Gly-Thr/Ala | 56 (26.8) | 32 (30.5) | 1.16 (0.62–2.16) | 0.64 | 1.18 (0.63–2.20) | 0.62 | |
| Gly/Glu-Thr/Thr | 31 (14.8) | 16 (15.2) | 1.05 (0.50–2.22) | 0.90 | 1.14 (0.53–2.43) | 0.74 | |
| Gly/Glu-Thr/Ala | 33 (15.8) | 10 (9.5) | 0.62 (0.27–1.42) | 0.26 | 0.60 (0.26–1.39) | 0.23 | |
| Gly/Gly-Ala/Ala | 11 (5.3) | 7 (6.7) | 1.30 (0.46–3.69) | 0.63 | 1.26 (0.44–3.62) | 0.67 | |
| Glu/Glu-Thr/Thr | 5 (2.4) | 8 (7.6) | 3.26 (0.98–10.84) | 0.05 | 3.81 (1.11–13.13)d | 0.03d | |
| Glu/Glu-Thr/Ala | |||||||
| Glu/Glu-Ala/Ala | |||||||
| Gly/Glu-Ala/Ala | 14 (6.7) | 3 (2.9) | 0.44 (0.12–1.64) | 0.22 | 0.42 (0.11–1.59) | 0.20 | |
| MLH3 rs175080-MSH6 | 210 (100) | 106 (100) | 0.032d | ||||
| rs1042821 | |||||||
| Pro/Pro-Gly/Gly | 32 (15.2) | 19 (17.9) | 1 (reference)e | 1 (reference)e | |||
| Pro/Pro-Gly/Glu | 26 (12.4) | 2 (1.9) | 0.13 (0.03–0.61)d | 0.01d | 0.11 (0.02–0.53)d | 0.01d | |
| Pro/Leu-Gly/Gly | 71 (33.8) | 36 (34.0) | 0.85 (0.43–1.71) | 0.66 | 0.81 (0.40–1.65) | 0.56 | |
| Pro/Leu-Gly/Glu | 35 (16.7) | 19 (17.9) | 0.91 (0.41–2.03) | 0.83 | 0.94 (0.41–2.13) | 0.88 | |
| Pro/Pro-Glu/Glu | 5 (2.4) | 8 (7.5) | 2.70 (0.77–9.44) | 0.12 | 3.09 (0.85–11.27) | 0.09 | |
| Pro/Leu-Glu/Glu | |||||||
| Leu/Leu-Glu/Glu | |||||||
| Leu/Leu-Gly/Gly | 24 (11.4) | 13 (12.3) | 0.91 (0.38–2.20) | 0.84 | 0.83 (0.34–2.03) | 0.68 | |
| Leu/Leu-Gly/Glu | 17 (8.1) | 9 (8.5) | 0.89 (0.33–2.39) | 0.82 | 0.89 (0.33–2.43) | 0.82 | |
| MSH4 rs5745325-MSH6 | 210 (100) | 106 (100) | 0.149 | ||||
| rs1042821 | |||||||
| Ala/Ala-Gly/Gly | 53 (25.2) | 36 (34.0) | 1 (reference)e | 1 (reference)e | |||
| Ala/Ala-Gly/Glu | 41 (19.5) | 20 (18.9) | 0.72 (0.36–1.42) | 0.34 | 0.74 (0.37–1.47) | 0.39 | |
| Ala/Thr-Gly/Gly | 59 (28.1) | 26 (24.5) | 0.65 (0.35–1.21) | 0.18 | 0.66 (0.35–1.23) | 0.19 | |
| Ala/Thr-Gly/Glu | 30 (14.3) | 7 (6.6) | 0.34 (0.14–0.87)d | 0.02d | 0.35 (0.14–0.88)d | 0.03d | |
| Ala/Ala-Glu/Glu | 12 (5.7) | 11 (10.4) | 1.35 (0.54–3.39) | 0.52 | 1.43 (0.56–3.66) | 0.45 | |
| Ala/Thr-Glu/Glu | |||||||
| Thr/Thr-Gly/Glu | |||||||
| Thr/Thr-Glu/Glu | |||||||
| Thr/Thr-Gly/Gly | 15 (7.1) | 6 (5.7) | 0.59 (0.21–1.66) | 0.32 | 0.60 (0.21–1.70) | 0.33 | |
a
Only combined genotypes presenting significant findings are shown.
b
P-value for cases vs. control group determined by two-sided Fisher's exact test (whenever 2×2 contingency tables are possible) or χ2 test (remaining cases).
c
ORs were adjusted for gender (male and female), age (<30, 30–49, 50–69, ≥70 years) and smoking status (non-smoker and smoker).
d
Significant results (P<0.05) highlighted in bold.
e
The reference comparator for OR calculations. DTC, well-differentiated thyroid cancer; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.